加载中
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
前收盘价
US$2.72
−US$0.03 · -1.09%
盘中时间采用ET。市场数据可能有所延迟。
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
日内区间
当前US$2.72
52周区间
当前US$2.72
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
48
合理估值
情绪
44
多空交织
风险
66
高风险
动量
16
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
日内区间
当前US$2.72
52周区间
当前US$2.72
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 6693 USD | 1.5万 USD | 2.56万 USD | 2.25万 USD |
| 毛利 | — | −6693 USD | −1.5万 USD | −2.56万 USD | −2.25万 USD |
| 研究与开发 | 942.87万 USD | 1053.54万 USD | 1761.66万 USD | 1151.01万 USD | 897.09万 USD |
| 销售、一般及管理费用 | 608.69万 USD | 1063.2万 USD | 1344.4万 USD | 1229.51万 USD | 1167.67万 USD |
| 营业费用 | 1551.56万 USD | 2116.75万 USD | 3106.06万 USD | 2380.51万 USD | 2064.76万 USD |
| 利息收入 | — | 6.36万 USD | 21.51万 USD | 9.01万 USD | 5133 USD |
| 利息支出 | 73.99万 USD | — | — | — | — |
| 折旧和摊销 | — | 6693 USD | 1.5万 USD | 2.56万 USD | 2.25万 USD |
| 营业利润 | −1551.56万 USD | −2117.42万 USD | −3107.56万 USD | −2383.07万 USD | −2067.01万 USD |
| 净利润 | −1622.9万 USD | −2111.12万 USD | −3086.05万 USD | −2374.06万 USD | −2066.5万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年7月16日 | 1:22 | — | — |
股票拆分 | 2025年10月21日 | 1:50 | — | — |
股票拆分 | 2024年2月2日 | 1:40 | — | — |
已生效 2026年7月16日
1:22
已生效 2025年10月21日
1:50
已生效 2024年2月2日
1:40
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
